Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 13% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (607 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerpatientstatuspriortherapy
  Phrases that lowered it: productperiodrangeuse ofmoderate
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 4.5% (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 58.5% (lowers risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 31 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor's past trials: 199 (lowers risk) · Sponsor's track record
• Primary purpose: supportive care (lowers risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 3 (lowers risk) · Design
• Collaborators: 2 (lowers risk) · Design
• Keywords listed: 17 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Blinding: double (raises risk) · Design
• Disease area, urogenital: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors NCT04493333 · started 2021 · scored riskier than 64% of active trials terminated
• An Efficacy Study of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy NCT02497547 · started 2014 · scored riskier than 7% of active trials completed
• Study to Evaluate Efficacy of Vagitocin in Postmenopausal Women With Vulvovaginal Atrophy Symptoms NCT04629885 · started 2016 · scored riskier than 6% of active trials completed
• Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis NCT03294538 · started 2016 · scored riskier than 5% of active trials completed
• Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo NCT01779947 · started 2012 · scored riskier than 8% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.